{
  "paper_id": "PMC11791746",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791746/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "A, PGRMC1 is overexpressed in human breast cancers of the basal subtype using PAM50. TMEM97 has the highest expression in luminal B tumors. B, PGRMC1 is overexpressed in hormone receptor–negative cancers. LDLR expression is highest in ER−/HER2+. TMEM97 has the highest expression in ER+/HER2+ tumors. C, PGRMC1 is overexpressed in smaller higher-grade tumors. LDLR and TMEM97 expression is highest in higher-grade tumors.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/cb6bb8796481/crc-23-0562_f1.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/cb6bb8796481/crc-23-0562_f1.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/cb6bb8796481/crc-23-0562_f1.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/cb6bb8796481/crc-23-0562_f1.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/cb6bb8796481/crc-23-0562_f1.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11791746/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/cb6bb8796481/crc-23-0562_f1.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "PGRMC1 is associated with early breast cancer relapse in a proliferation-dependent manner. Effect size estimates were aggregated across datasets by meta-analysis to determine the risk of relapse within 5 years from all cancers. A, Association of PGRMC1 with early breast cancer relapse. B, Association of PGRMC1 with early breast cancer relapse within the basal subtype. C, Association of PGRMC1 with early relapse adjusted for estimated proliferation. JRH, John Radcliffe Hospital.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/7404ebce8526/crc-23-0562_f2.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/7404ebce8526/crc-23-0562_f2.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/7404ebce8526/crc-23-0562_f2.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/7404ebce8526/crc-23-0562_f2.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/7404ebce8526/crc-23-0562_f2.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11791746/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/7404ebce8526/crc-23-0562_f2.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3.",
      "caption": "TMEM97 is associated with early breast cancer relapse in a proliferation-dependent manner. Effect size estimates were aggregated across datasets by meta-analysis to determine the risk of relapse within 5 years. A, TMEM97 is associated with early breast cancer relapse only in ER+ tumors. B, TMEM97 is associated with early breast cancer relapse only in ER+/HER2− tumors. C, Association of TMEM97 with early breast cancer relapse in ER+/HER2− tumors adjusted for proliferation. JRH, John Radcliffe Hospital; RFS, recurrence-free survival.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/18c9b60673bb/crc-23-0562_f3.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/18c9b60673bb/crc-23-0562_f3.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/18c9b60673bb/crc-23-0562_f3.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/18c9b60673bb/crc-23-0562_f3.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/18c9b60673bb/crc-23-0562_f3.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11791746/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/18c9b60673bb/crc-23-0562_f3.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Figure 4.",
      "caption": "PAM50, derived Oncotype DX, and a new proliferation score (Prolif224) were all similarly related to RFS. JRH, John Radcliffe Hospital; RFS, recurrence-free survival.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/d62da8b133d3/crc-23-0562_f4.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/d62da8b133d3/crc-23-0562_f4.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/d62da8b133d3/crc-23-0562_f4.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/d62da8b133d3/crc-23-0562_f4.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/d62da8b133d3/crc-23-0562_f4.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11791746/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/d62da8b133d3/crc-23-0562_f4.jpg"
    },
    "figure_5": {
      "figure_number": "Figure 5",
      "title": "Figure 5.",
      "caption": "Proposed mechanism of a secondary pathway for cholesterol internalization utilized by rapidly proliferating cells demonstrating an “accelerated rate mechanism” of receptor mediated endocytosis. Created in BioRender. McDonald, E. (2024) https://BioRender.com/i39x933.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/06cd0dafeff5/crc-23-0562_f5.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/06cd0dafeff5/crc-23-0562_f5.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/06cd0dafeff5/crc-23-0562_f5.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/06cd0dafeff5/crc-23-0562_f5.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig5",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/06cd0dafeff5/crc-23-0562_f5.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11791746/images/figure_5.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/837f/11791746/06cd0dafeff5/crc-23-0562_f5.jpg"
    }
  },
  "claims": [
    {
      "sentence": "TMEM97 has the highest expression in luminal B tumors (Fig. 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In an analogous manner, PGRMC1 was expressed at higher levels in ER− tumors, PR− tumors, and ER−/HER2− tumors (Fig. 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "PGRMC1 was also expressed at higher levels in tumors of higher grade (P = 2.5 × 10−14) and smaller size (P = 4.7 × 10−7; Fig. 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In the integrated dataset, LDLR and TMEM97 also had the highest expression in ER− disease (P = 4.7e−14 and P = 0.041, respectively; Fig. 1B); LDLR and TMEM97 were also each expressed at higher levels in tumors of higher grade (P = 1.1 × 10−08 and 6.1 × 10−64, respectively; Fig. 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The results demonstrated that PGRMC1 expression is associated with a higher risk of early relapse (within 5 years) across all patients with breast cancer [HR = 1.25; 95% confidence interval (CI) = 1.12–1.39; P = 6.4 × 10−5; Fig. 2A].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Within the basal subtype, PGRMC1 expression was also associated with relapse (HR = 1.29; 95% CI = 1.04–1.60; P = 0.018; Fig. 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The risk of early recurrence with TMEM97 was present only in ER+/HER2− disease (HR = 1.5; 95% CI = 1.35–1.67; P = 5.4−14) and ER+ malignancies (HR = 1.49; 95% CI = 1.31–1.68; P = 3.1−10) and was not present in ER−/HER2− (HR = 1.05; 95% CI = 0.88–1.25; P = 0.63) or ER− disease (HR = 1.02; 95% CI = 0.89–1.17; P = 0.75; Fig. 3A and B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The CIs for PAM50, Oncotype DX, and our new proliferation signature were from 0.63 to 0.66, which is moderate and reasonable, consistent with these prior reported data (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The CIs for PAM50, Oncotype DX, and our new proliferation signature were from 0.63 to 0.66, which is moderate and reasonable, consistent with these prior reported data (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "This is when the sigma-2–PGRMC1–LDL complex becomes crucial, as it can enhance the rate of internalization by up to tenfold (Fig. 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "This is when the sigma-2–PGRMC1–LDL complex becomes crucial, as it can enhance the rate of internalization by up to tenfold (Fig. 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 5,
    "claims_count": 11,
    "images_downloaded": 5,
    "tables_filtered": 16
  }
}